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Homozygous deficiencies of complement C4A or C4B are detected in 1–10% of popula-
tions. In genome-wide association studies C4 deficiencies are missed because the genetic
variation of C4 is complex. There are no studies where the clinical presentation of these
patients is analyzed. This study was aimed to characterize the clinical features of patients
with homozygous C4A or C4B deficiency.
Material and methods
Thirty-two patients with no functional C4A, 87 patients with no C4B and 120 with normal
amount of C4 genes were included. C4A and C4B numbers were assessed with genomic
quantitative real-time PCR. Medical history was studied retrospectively from patients’ files.
Results
Novel associations between homozygous C4A deficiency and lymphoma, coeliac disease
and sarcoidosis were detected. These conditions were present in 12.5%, (4/32 in patients
vs. 0.8%, 1/120, in controls, OR = 17.00, 95%CI = 1.83–158.04, p = 0.007), 12.5% (4/32 in
patients vs. 0%, 0/120 in controls, OR = 1.14, 95%CI = 1.00–1.30, p = 0.002) and 12.5%,
respectively (4/32 in patients vs. 2.5%, 3/120 in controls, OR = 5.571, 95%CI = 1.79–2.32,
p = 0.036). In addition, C4A and C4B deficiencies were both associated with adverse drug
reactions leading to drug discontinuation (34.4%, 11/32 in C4A-deficient patients vs. 14.2%,
17/120 in controls, OR = 3.174, 95%CI = 1.30–7.74, p = 0.009 and 28.7%, 25/87 in C4B-
deficient patients, OR = 2.44, 95%CI = 1.22–4.88, p = 0.010).
Conclusion
This reported cohort of homozygous deficiencies of C4A or C4B suggests that C4 deficien-
cies may have various unrecorded disease associations. C4 gene should be considered as
a candidate gene in studying these selected disease associations.
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Introduction
The complement system is an essential humoral defence mechanism that is involved in main-
taining tissue homeostasis, innate immune reactions, activation and propagation of adaptive
immune reactions as well as in non-immune functions such as lipid metabolism, synapsis matu-
ration and blood coagulation. The complement cascade can be activated by three pathways; clas-
sical, alternative or lectin pathway. To maintain these varied functions, the complement system
is meticulously regulated. Dysfunctions in the complement system have been linked with risk of
various infections, autoimmune conditions such as systemic lupus, rheumatoid arthritis and
asthma, as well as sepsis, ischemia-reperfusion injury and age-related macular degeneration [1].
The complement component C4 plays a role in the activation of classic and lectin pathways,
leading to cleavage of C2, C3 and C5. The C4 protein is encoded by two slightly different adja-
cent genetic loci, C4A and C4B, located within the major histocompatibility complex (MHC)
class III region on the short arm of chromosome 6 (MIM +120810 and 120820, respectively)
[2–4]. Consequently, there are both C4A and C4B proteins circulating in the blood and tissues,
which together form the commonly measured C4 concentration. Most individuals have four
C4 genes. Approximately 60% of healthy individuals have two C4A and two C4B genes [5, 6].
In the Finnish population, 59% individuals have one C4A and one C4B gene in a chromosome
[7]. However, the total number of C4 genes may vary between 2 and 8 [8].
The presence of no functional C4A or C4B genes causes complete C4A or C4B deficiency
and is called homozygous C4 deficiency. The presence of one C4A or C4B gene is called hetero-
zygous C4A or C4B deficiency [8]. Compared to deficiencies of other complement components
of the classical pathway, homozygous C4A and C4B deficiencies are rather common [9].
Homozygous C4A deficiency is detected in 1–6% and homozygous C4B deficiency in 1–10%
of studied healthy populations [7, 10–15]. Heterozygous C4 deficiency is more common; 12–
21% of healthy populations are heterozygously C4A-deficient and 20–41% of the populations
have a heterozygous deficiency of C4B [8, 10, 11, 13–15]. Deficiency of all C4 genes (neither
functional C4A nor C4B genes present) is extremely rare and to date, only 28 patients have
been described in the literature [9, 16, 17]. Patients with no functional C4 genes have been
reported to have SLE (n = 17), SLE-like disease (n = 5), kidney diseases (n = 6), and repeated
or invasive infections (n = 7) [9].
In disease association studies, homozygous and heterozygous C4A or C4B deficiencies are
usually grouped together under the general term of “C4A or C4B deficiency”. The studies distin-
guishing homozygous C4 deficiencies have repeatedly reported association between homozygous
C4A deficiency and systemic lupus erythematosus (SLE)[10, 18–20]. There is also one study
reporting association with pulmonary tuberculosis [21] and one with capillary leak syndrome
during cardiopulmonary bypass in children [22]. Homozygous C4B deficiency has been associ-
ated with coronary artery disease [23], glomerular disease and infections in case reports [24, 25].
However, the number of cases in these reports is very low, ranging from three to twenty-six.
This study was aimed to systematically assess the clinical features and characteristics as well
as disease associations of patients with either homozygous C4A or C4B deficiency. We detected




Individuals from Helsinki University Hospital with homozygous C4A (n = 32) or C4B (n = 87)
deficiency were identified from our Laboratory’s database between years 2004 and 2011 by
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screening 2173 individuals. Randomly selected individuals with two functional C4A and C4B
genes (n = 120) from the same record served as controls. Cases with two C4A and C4B genes
were chosen as controls as this is the most common genetic combination of the background
population and in order to make the control population as homogenous as possible to ease the
comparisons between cases and controls. The controls were selected over the same time range
as the first and middle sample of a given month. The Local Ethics Committee’s approval was
not needed due to anonymous register-like nature of the study.
Medical history
The medical records were retrospectively evaluated for diagnosed clinical diseases and descrip-
tive symptoms. The medical history and diagnoses were individually retrieved as defined by
the treating clinician. The searched diagnoses/conditions are listed below.
Autoimmune conditions: SLE, rheumatoid arthritis, spondylarthritis ancylopoetica, sero-
negative spondylarthropathy (SSA), type I diabetes mellitus, coeliac disease, autoimmune gas-
tritis, primary biliary cirrhosis, autoimmune hepatitis, autoimmune haemolytic anaemia,
autoimmune neutropenia, idiopathic thrombocytopenic purpura, glomerulonephritis, IgA
nephropathy and asthma.
Infections were categorized as 1) invasive infections including bacteremia, pneumonia and
meningitis, 2) recurrent central nervous system Herpes simplex virus (HSV) manifestations,
and 3) recurrent tonsillitis or sinusitis which required operative treatment.
Neurological diagnoses and signs: Epilepsy, multiple sclerosis, vertigo, migraine or severe
headache, spasticity or ataxia of unknown causes, numbness, myalgia, paresthesias and paraly-
ses of unknown causes.
Gastrointestinal diseases and signs: inflammatory bowel disease, abdominal pain necessitat-
ing hospital investigations, irritable bowel syndrome, and recurrent Clostridium difficile colitis.
Other symptoms: reactive arthritis, hypothyroidism.
Adverse drug effects: Any mention of adverse drug reactions leading to drug discontinua-
tion (and avoidance), toxic reactions and side effects were recorded.
Allergies: Reported by patients included mainly pollen and/or animal epithelium, nickel
and iodine.
Psychological conditions: Psychosis, schizophrenia, severe depression and anxiety.
Gene analyses
The copy numbers of C4A, C4B and the most common silencing mutation of C4A,CTins, were
recorded with a validated real-time quantitative polymerase chain reaction as described in
detail elsewhere [7]. In brief, genomic DNA was amplified with SYBR1 Green labelling using
isotype-specific primers (Rotor-Gene 3000, Qiagen, Austria). The resulting fluorescence curve
was analysed in relation to controls and housekeeping gene fluorescence recordings (Rotor-
Gene, software v 6.0, Qiagen). The number of functional C4Awas determined by reducing the
number of CTins copies from the total number of C4A. Besides the CTins, no other C4muta-
tions were screened,.
Human leucocyte antigen (HLA) alleles (HLAB-27,-35,HLA-DRB101, 03, 04, 15)
were characterized with similar quantitative real-time PCR procedure using allele-specific
primers and performed in our HLA-laboratory having accreditation by the European Federa-
tion for Immunogenetics (EFI). HLA-genotyping data was available from 50% (16/32) of C4A-
deficient patients, 51% (44/87) of C4B-deficient patients and 46% (55/120) of the controls. The
HLA data was available if the treating physician had requested for these assays based on clinical
judgement.
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Laboratory parameters
Immunoglobulin levels (IgG, M, A and E) and antibody levels againstHerpes simplex viruses
(HSV, types 1 and 2), Varicella zoster virus (VZV), nuclear antigens (ANA), neutrophilic cyto-
plasmic components (ANCA) and rheumatic factor (RF) were collected from medical reports.
An abnormal value was indicated if differed from reference values (6.8–15 g/l for IgG, 0.36–
2.59 g/l for IgM, 0.88–2.84 g/l for IgA,<1 g/l for IgE, 0.71–1.41 g/l for C3, 0.15–0.5 g/l for C4,
positive titre recording (95th percentile) for HSV or VZV, 1:320 for ANA and 1:20 for ANCA,
all positive titres represented about 95th percentile level in Finnish population). All laboratory
recordings were done by the standard procedures of the accredited diagnostic laboratory of
Helsinki and Uusimaa Hospital District (HUSLAB).
Statistical analyses
Statistical analyses, Chi-square, Student’s t- and Mann–Whitney U test, were performed when
appropriate using PASW statistics (v. 20.0). The continuous variables that were normally dis-
tributed were also tested with Student’s t-test. Two-tailed p-value <0.05 was considered statis-
tically significant. Odd’s ratios (OR) and their 95% confidence intervals (95%CI) were assessed
with Chi-square statistics. The number of autoimmune conditions was assessed with Linear-
by-linear association. Sex, decreased complement activity of mannan binding lectin pathway,
genetic backgrounds of C4 deficiencies and the simultaneous presence ofHLA-B35 and
HLA-DRB101were studied in subgroup analyses of C4A or C4B deficiency and compared
with the same subgroups in controls. In most cases, all available laboratory parameters were
included except for complement activity analyses, where the cases were excluded listwise.
Results
Age- and sex distributions were similar in all groups. The majority (>75%) of the samples
were from Helsinki University Hospital, Division of Infectious Diseases, corresponding to our
Laboratory’s general distribution (Table 1).
Both patient groups with homozygous C4A or C4B deficiency had lower blood C4 levels
(Table 1). Patients with homozygous C4A deficiency had autoantibodies more often than con-
trols (33.3%, 10/32 vs. 16.5%, 17/120, p = 0.044 for positive ANCA or ANA autoantibodies,
Table 1). In addition, the IgG and IgM immunoglobulin levels seemed to be more often abnor-
mal (elevated or lowered) among patients with homozygous C4A deficiency as compared to
controls. Patients with homozygous C4B deficiency were more often recorded to have statisti-
cally lower complement C3 activation values (Table 1), but the frequency of abnormally low
C3 (i.e. below the laboratory reference range) was similar in all groups (data not shown).
Autoimmune manifestations
Homozygous C4A deficiency was associated with increased number of autoimmune condi-
tions (p = 0.047, Table 2). The specific autoimmune conditions were SLE (18.8%, 6/32 vs.
5.8%, 7/120 in C4A deficient patients and controls, respectively, OR = 3.75, 95%CI = 1.16–
12.01, p = 0.031) and coeliac disease (12.5%, 4/32 vs. 0%, 0/120 in C4A deficient patients and
controls, p = 0.002).
Homozygous C4B deficiency was not associated with autoimmune condition(s). Although
there was increased incidence of symptoms detected post-infectiously reminiscent of autoim-
mune diseases (13.8% vs. 4.17% in C4B deficient patients and controls, respectively, OR = 3.68,
95% CI = 1.25–10.87, p = 0.013). These conditions are listed in detail in S1 Table.
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Infections
No differences in rate of recurrent or invasive infections were apparent between patients with
homozygous C4A or C4B deficiency and controls. Central nervous systemHerpes simplex virus
infections were marginally (but not statistically) increased in both C4 deficient groups (6.3%,
2/32, 5.7%, 5/87 and 1.7% 2/120 in C4A deficient, C4B deficient and in controls, respectively,
data not shown).HSV type 1 was the causative agent in two C4A-deficient andHSV 2 in five
C4B-deficient patients.
Other conditions
In patients with homozygotic C4A deficiency, lymphomas were significantly more common
than in other groups (12.50%, 4/32 in C4A deficient vs. 0.8%, 1/120 in controls OR = 17.00,
95%CI = 1.83–158.04, p = 0.007, Table 3). However, no specific lymphoma type could be iden-
tified. In addition, sarcoidosis was more commonly diagnosed in C4A deficient patients
(12.50%, 4/32 vs. 2.50%, 3/120 OR = 5.571, 95%CI = 1.1789–26.3, p = 0.036, for C4A deficient
patients and controls, respectively). No differences in frequencies of recorded neurological,
ocular or psychiatric diagnoses were apparent.







n (%) or mean (SD) n (%) or mean (SD) n (%) or mean
(SD)
P = (C4A-deficient vs.
Controls)
P = (C4B-deficient vs.
Controls)
Age (years) 45.25 (18.0) 44.08 (14.6) 43.92 (15.2) 0.778 0.900
Females 22 (68.8) 59 (67.8) 72 (60.0) 0.365 0.181
Samples ordered from 0.036 0.615
Infectious diseases 25 (78.2) 75 (86.2) 108 (90.0)
Internal medicine 1 (3.1) 7 (8.0) 6 (5.0)
Other departments or private
sector
6 (18.1) 5 (5.7) 6 (5.0)
Complement values 
Plasma C3 g/l 1.19 (0.4) 1.11 (0.34) 1.21 (0.4) 0.263 0.025
Low C3 (%) 2 (6.9) 7 (8.5) 4 (3.6) 0.604 0.209
Plasma C4 g/l 0.17 (0.1) 0.2 (0.1) 0.27 (0.1) <0.0001 <0.0001
Low C4 (%) 5 (17.2) 15 (18.5) 2 (1.8) 0.005 0.0001
Abnormal immunoglobulin
levels
IgG (%) 10 (35.7) 17 (20.7) 19 (17.0) 0.029 0.461
IgM (%) 8 (28.6) 11 (13.3) 11 (9.9) 0.026 0.436
IgA (%) 6 (21.4) 11 (13.4) 13 (11.7) 0.218 0.682
Positive autoimmune
antibodies
ANA or ANCA (%) 10 (33.3) 14 (17.5) 17 (16.5) 0.044 0.836
Data is presented as median (SD) for age, plasma C3, plasma C4 and as n (%) for other variables.C4A, complement component C4A; C4B, Complement component
C4B; C3, complement component 3; Abnormal immunoglobulin levels, either elevated or lowered; IgG, Immunoglobulin class G; IgM, Immunoglobulin class M; IgA
Immunoglobulin class A; ANA, anti-nuclear antibodies; ANCA, anti-neutrophilic cytoplasmic antibodies.
 OR = 2.719, 95%CI = 1.087–6.804
 OR = 3.636, 95%CI = 1.299–10.181
 OR = 2.53, 95%CI = 1.00–6.35
 For cut-offs for abnormal C3, C4, IgG, IgM and IgA leves, see text for Laboratory Parameters
https://doi.org/10.1371/journal.pone.0199305.t001
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Adverse drug reactions
Patients with homozygous C4A or C4B deficiency were recorded to have more adverse effects
leading to drug discontinuation than controls (34.38%, 11/32 in C4A deficient, 28.74%, 25/87
in C4B deficient vs. 14.17%, 17/120 in controls, p = 0.009 for C4A-deficient vs. controls,
p = 0.010 for C4B-deficient vs. controls, Table 4). The discontinued medications were most
often antibiotics. For C4A deficient patients, statistical significance was not attained for any
individual category. Patients with C4B deficiency, however, had significantly more often dis-
continued antimicrobial agents than the controls (25%, 22/87 vs. 10%, 12/120, p = 0.003). This
difference seemed to be explained by the markedly increased intolerance to sulphonamides
(12.8%, 11/87 vs. 0.8%, 1/120, OR = 17.45, 95%CI = 2.21–138.0, p<0.001) and doxycycline
(8.1%, 7/87 vs. 0.8%, 1/120, OR = 10.544, 95%CI = 1.27–87.37, p = 0.001 for C4B-deficient vs.
controls).







n (%) n (%) n (%) P = (C4A-deficient vs.
controls)
P = (C4B-deficient vs.
controls)
Any autoimmune condition 21 (65.6) 42 (48.3) 55 (45.8) 0.047 0.728
Systemic Lupus
Erythematosus
6 (18.8) 8 (9.20) 7 (5.8) 0.031 0.357
Coeliac disease 4 (12.5) 0 (0) 0 0.002 1.000
Hypothyreoidism 2 (6.3) 6 (6.9) 10 (8.3) 1.000 0.702
Seronegative
spondyloarthropathy
3 (9.4) 7 (8.0) 4 (3.3) 0.162 0.208
Post-infective prolonged
symptoms
3 (9.4) 12 (13.8) 5 (4.2) 0.241 0.013
Reactive arthritis 1 (3.13) 4 (4.6) 1 (0.8) 0.312 0.164
 OR (95%CI) = 2.26 (1.00–5.09)
 OR (95%CI) = 3.75 (1.16–12.01)
 OR (95%CI) = 1.14 (1.00–1.30)
 OR (95%CI) = 3.68 (1.25–10.87)
https://doi.org/10.1371/journal.pone.0199305.t002







n (%) n (%) n (%) P = (C4A-deficient vs.
controls)
P = (C4B-deficient vs.
controls)
Any malignancy 6 (18.8) 9 (10.3) 8 (6.7) 0.077 0.442
Lymphoma 4 (12.5) 1 (1.1) 1 (0.8) 0.007 1.000
Sarcoidosis 4 (12.5) 4 (4.6) 3 (2.5) 0.036 0.453
Ischemia 2 (6.3) 4 (4.6) 3 (2.5) 0.283 0.394
Epilepsy 1 (3.1) 4 (4.6) 4 (3.3) 1.000 0.621
Migraine 0 (0.0) 2 (2.3) 3 (2.5) 1.000 1.000
Psychiatric
diagnosis
0 (0.0) 4 (4.6) 3 (2.5) 1.000 0.453
 OR = 3.231, 95%CI = 1.032–10.115
 OR = 17.00, 95%CI = 1.83–158.04
 OR = 5.57, 95%CI = 1.18–26.3
https://doi.org/10.1371/journal.pone.0199305.t003
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Complement activity
The activities of complement activation pathways were assessed by the treating clinician in one
fourth of the study populations. This number is too small to draw conclusions. The available
data is depicted in S2 Table.
C4 deficiency and remaining C4 genes
The genetic background for homozygous C4 deficiency was variable (S3 Table). Almost all
patients with homozygous C4A deficiency had two copies of C4B genes (93.75%, 30/32). Most
patients with homozygous C4B deficiency had three copies of C4A genes (68.97%, 60/87)
whereas the rest had two C4A genes and one patient had four C4A genes.
Discussion
In this relatively large cohort of patients with homozygous C4A or C4B deficiency, we were
able to discover novel disease associations as well as replicate some previously known associa-
tions. Where the previous genetic studies of C4 deficiency have included patients with homo-
zygous and heterozygous C4 deficiency, this is one of the largest cohorts gathering only
patients with homozygous C4A or C4B deficiency (i.e. no functional C4A or C4B genes at all).
Because the serum levels and the gene numbers do not correlate well, in selecting patients







n (%) n (%) n (%) P = (C4A-deficient vs.
controls)




11 (34.4) 25 (28.7) 17 (14.2) 0.009 0.010
Antimicrobial
discontinuation
Sulfonamides 2 (6.9) 11 (12.8) 1 (0.8) 0.097 0.0003
Doxycycline 1 (3.5) 7 (8.1) 1 (0.8) 0.352 0.010
Beta-lactamases 4 (13.8) 11 (12.8) 8 (6.7) 0.250 0.134
Macrolides 0 (0) 6 (7.0) 2 (1.7) 1.000 0.070
Other 0 (0) 4 (4.7) 2 (1.7) 1.000 0.238
Any antimicrobial 6 (20.7) 22 (25.6) 12 (10.0) 0.121 0.003
Anti-inflammatory
NSAID 2 (6.9) 3 (3.4) 2 (1.7) 0.195 0.652
ASA 1 (3.5) 5 (5.7) 4 (3.3) 1.000 0.497
Other
Any other 0 (0) 8 (9.2) 5 (4.2) 0.585 0.141
NSAID, non-steroidal anti-inflammatory drug; ASA, acetylic salicylic acid
 OR (95%CI) = 3.17 (1.3–7.7)
 OR (95%CI) = 2.44 (1.22–4.88)
 OR (95%CI) = 17.45 (2.21–137.96)
 OR (95%CI) = 10.54 (1.27–87.37)
 OR (95%CI) = 3.09 (1.44–6.67)
 Other intolerated medicines for C4B deficient (barium, alendronate, metamizole + pitophenone, tramadol, antibiotics for tuberculosis, valaciclovir,
methylprednisolone). For controls the intolerated medicines (angiotensinogen II inhibitor, beta-blocker, lidocaine and myasthenia combination drugs).
https://doi.org/10.1371/journal.pone.0199305.t004
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without any C4A or C4B genes, we are hoping to better clarify disease associations of these
conditions.
Biological effect of homozygous C4 deficiencies
Although C4A and C4B proteins differ only by 4 amino acids, they exhibit marked differences
in chemical reactivity to substrates. Activated C4A protein forms a covalent amide bond with
amino groups on peptide antigens, whereas activated C4B binds more efficiently to hydroxyl
group containing substrates of carbohydrate antigens [2]. Accordingly, homozygous defi-
ciency of C4A has been reported to associate with increased frequency of autoimmune dis-
eases, whereas homozygous C4B deficiency has been associated with increased susceptibility of
bacterial and enveloped viral infections. However, the reported disease associations of genetic
C4B deficiency (homozygous and heterozygous deficiency combined) include also common
and complex diseases such as psychiatric disorders and atherosclerosis [26–28].
In our study, somewhat surprisingly, the homozygous deficiency of C4A or C4Bwere not
associated with significantly increased frequency of infectious or autoimmune disease burden
(except for the association between SLE and C4A deficiency), at least when compared with
hospitalized controls. If homozygous C4A deficient patients would have significantly aberrant
immune clearance, the patients could be expected to exhibit features of aberrant autoimmune
reactions, despite the redundancy of the immune system. Correspondingly, the homozygous
C4B deficient patients would be expected to have at least some kind of signal of increased rate
of infections. We could not see such differences, but due to the lack of healthy controls, we
were not able to reliably assess the role of infections in this material.
For homozygous C4A deficient patients in this study population, the majority of patients
had two copies of C4B. Thus, C4B copy number did not seem to compensate for the lacking
C4A genes. However, it is not known, to which extent the local production of C4B could be
increased due to increased demand. In the homozygous C4B deficient patients, the majority
did have one “extra” copy of C4A (three copes in total). Whether this “increase” in C4A copies
could explain for the small amount of disease associations with homozygous C4B deficiency
detected in this study remains unknown. In addition, the plasma C4 protein concentration is
only partly determined by C4 gene copy number and is also affected by the size variations as
well [29, 30]. Unfortunately, the size variation of C4 genes and the activities of different com-
plement activation routes were not routinely assessed in this study. In a steady stage, this
would naturally be very informative. In addition, a C4-independent activation route of the
complement system has been described [31].
As with many other studies assessing the HLA genes, we must account for the surrounding
gene region. HLA genes are inherited in tightly connected “haploblocks”, in which the normal
laws or genetic recombination do not apply [32, 33]. Without extensive and detailed data or
some kind of biological modelling, in mere association studies, the causative nature of the
gene marker in question can only be contemplated. Correspondingly, even with the strongest
known association between C4A deficiency and SLE, the surrounding genetic landscape is
playing an essential role in disease susceptibility [10]. In addition, it has recently been shown
that despite the linkage with the surrounding genes, C4 deficiency is not reliably assessed in
GWAS [10]. This makes both the disease association studies and analyses more challenging.
Homozygous C4A deficiency
We discovered that patients with homozygous C4A deficiency had a significantly increased
prevalence of lymphomas, with an OR of 17. To our knowledge, this association has not been
previously reported. However, the HLA gene region has been linked with various types of
Clinical features of homozygous C4 deficiency
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haematological malignancies in multiple studies. Unfortunately, we could not reliably classify
the subtypes of these lymphomas and therefore, were unable to further assess the specific dis-
ease associations.
It has to be borne in mind that our material consists of relatively small number of patients.
In addition, our patients were suffering from difficult or recurrent infections, and the majority
was treated in the Department of Infectious Diseases. Even though the control population con-
sisted of similar patients and did not show increased incidence on lymphomas, we cannot
speculate, whether the association between homozygous C4A deficiency and haematological
malignancy could be mediated or underlined by infections the patients were suffering from.
We found the increased incidence of coeliac disease in patients with homozygous C4A defi-
ciency. HLA class II alleles are known to confer strong risk for coeliac disease and HLA testing
is recommended in exclusion of coeliac disease in certain patients [34]. The C4A deficiency
has been linked with coeliac disease, most likely due to linkage disequilibrium with the sur-
rounding HLA-alleles [35]. The common ancestral haplotype (AH8.1) has been associated
with coeliac disease and various other autoimmune conditions including sarcoidosis [36, 37].
We were able to replicate the finding that the patients with homozygous C4A deficiency had
almost six-fold more sarcoidosis corresponding to the previous study in Finnish sarcoidosis
patients [38]. As with many other disease association studies, based on the data at hand, it is
difficult to state, which of the associated gene markers, if any, comprises the true causative
factor.
We also were able to confirm the previously reported associations between homozygous
C4A deficiency and autoimmune condition SLE [10, 18, 19, 20]. Homozygous deficiency of
C4A is a predisposing factor for SLE, but not all homozygous C4A deficient patients develop
SLE [10, 18]. The increased incidence of autoantibodies in the homozygous C4A deficient
patients supports the role of C4A deficiency in autoimmunity.
In previous studies in Finland, heterozygous C4A deficiency has been shown to associate
with recurrent or chronic respiratory tract infections [39]. We were not able to replicate these
findings in our material with patients with diseases necessitating hospital treatment. Whether
there would be an association if the control material would have consisted of general popula-
tion, remains unknown.
Homozygous C4B deficiency
In our study, patients with homozygous C4B deficiency seemed to have more intolerance to
sulphonamides and doxycycline as well as suffering more often from various post-infectious
symptoms. The association between drug discontinuation was strong; ORs ranged from 10 to
17. Although the term “post-infectious symptoms” is anything but exact it is an existing and
clinically difficult entity that is difficult to verify. The recorded symptoms ranged from vasculi-
tis to prolonged fever, arthralgia and myocarditis after infection. It is impossible to determine
the role of infection in these cases but in all of these cases, the symptomology had started soon
after bacterial or viral infection and could not be corrected by medical treatment. This corre-
sponds to our previous finding from a patient with persistent arthralgia and myalgia 6 months
after acute SINV infection [40].
The data on infection-proneness of C4 deficiency is controversial [41]. In the previous stud-
ies, (mostly homo- and heterozygous deficiency combined) C4B deficiency has been linked
with increased rate of invasive infections [27]. However, recent association studies have chal-
lenged this by inverse associations [21,41–43]. In our cohort, homozygous C4B deficient
patients did not have increased rate of invasive infections. Due to the biased nature of our data
with similar background of controls, we cannot reliably assess the role of homozygous C4B
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deficiency in meningitis or in invasive infections. According to our data, it seems however,
that homozygous C4B deficiency alone is not significant in causing invasive infections as only
a small part of C4B-deficient patients suffered from such infections.
Limitations
The limitations of our study are the relatively small number of homozygous C4A deficient
patients although this is among the largest clinical studies on homozygous C4 deficiencies, the
lack of complete HLA-types and of follow-up data. In addition, another limitation is that the
patient data was retrospectively retrieved from medical recordings. We cannot therefore evalu-
ate the medical conditions based on diagnostic criteria.
Due to the rarity of this genetic phenomenon (1–6%), a very large population cohort
(1666–10 000) should be screened to attain a population of 100 patients.
In addition, multiple hypotheses in multiple conditions were tested without correcting the
p-value, thus the validity of our findings has to be replicated in an independent patient sample.
However, as this study is hypothesis-forming rather than hypothesis-confirming, the p-value
correction for multiple testing does not need to be stringently followed. Although the back-
ground population is highly selected, both patients and controls were drawn from the same
cohort. Population- based screening and follow-up studies are needed to determine causality
and the applicability to general population. We do not intend to elucidate the disease associa-
tions, but merely characterize this population and launch new hypotheses.
Conclusion
Homozygous C4A and C4B deficiencies differ in their clinical characteristics and disease asso-
ciations. In addition to the previous disease associations, we discovered that homozygous C4A
deficiency might be associated with lymphoma and sarcoidosis and that homozygous C4B defi-
ciency might be associated with prolonged post-infectious symptoms and drug discontinua-
tion due to adverse reactions, which occurred mainly with antibiotics. These notions may
open novel pathways to assess the role of C4 in these conditions. Therefore, novel and larger
studies are warranted.
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